- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03341884
A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Participants
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Ipatasertib in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Subjects
Descripción general del estudio
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Florida
-
Miami, Florida, Estados Unidos, 33014
- Clinical Pharmacology of Miami, Inc.
-
-
Tennessee
-
Knoxville, Tennessee, Estados Unidos, 37920
- New Orleans Center for Clinical Research
-
-
Texas
-
San Antonio, Texas, Estados Unidos, 78215
- American Research Corporation Inc.
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- In good health (except for specific inclusion criteria related to hepatic impairment), as determined by the Investigator, based on no clinically significant findings from medical history, physical examination, 12-lead electrocardiogram, and vital signs
- Females will not be pregnant or breastfeeding, and must be either postmenopausal or agree to use a study-approved method of contraception from the time of signing the informed consent until 30 days after discharge
- Males will either be sterile or agree to use male condom with spermicide from check-in (Day -1) until 90 days following the dose of study drug
Additional Inclusion Criteria for Healthy Subjects Only:
- Liver enzyme tests must be less than or equal to the upper limits of normal
Additional Exclusion Criteria for Hepatic Impaired Subjects Only:
- Hepatic impairment must have a Child-Pugh score of 5 to 6 (mild), 7 to 9 (moderate), or 10 to 15 (severe) and have stable hepatic insufficiency within 1 month prior to Screening
Exclusion Criteria:
- History of ulcerative colitis or stomach or intestinal surgery or resection
- History of unstable diabetes mellitus
- History of alcoholism or drug addiction within 1 year prior to Check-in (Day -1)
- Use of oral, implantable, transdermal, or injectable contraceptives from the time of signing the informed consent (females only) or 10 days prior to Check-in through 45 days after the dose administration
- Poor peripheral venous access
- Receipt of blood products within 2 months prior to check-in
Additional Exclusion Criteria for Healthy Subjects Only:
- Use of any tobacco- or nicotine-containing products within 6 months prior to check-in and during the entire study
- Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder
Additional Exclusion Criteria for Hepatic Impaired Subjects Only:
- Any evidence of progressive liver disease that has worsened or is worsening within 1 month prior to the screening visit
- Participant has shown evidence of hepatorenal syndrome
- Ascites requiring paracentesis
- Participant has required treatment for GI bleeding within 12 months prior to Check-in
- Participant has required additional medication for hepatic encephalopathy within the 12 months (6 months for severe hepatic impairment) prior to check-in
- Total bilirubin levels >6 mg/dL
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Normal Hepatic Function
Participants with normal hepatic function will be administered a single oral dose of ipatasertib (100 mg).
|
A single oral dose of 100 mg ipatasertib will be administered.
Otros nombres:
|
Experimental: Mild Hepatic Impairment
Participants with mild hepatic impairment (Child-Pugh Class A, score of 5 to 6, inclusive) will be administered a single dose of ipatasertib (100 mg).
|
A single oral dose of 100 mg ipatasertib will be administered.
Otros nombres:
|
Experimental: Moderate Hepatic Impairment
Participants with moderate hepatic impairment (Child-Pugh Class B, score of 7 to 9, inclusive) will be administered a single dose of ipatasertib (100 mg).
|
A single oral dose of 100 mg ipatasertib will be administered.
Otros nombres:
|
Experimental: Severe Hepatic Impairment
Participants with severe hepatic impairment (Child-Pugh Class C, score of 10 to 15, inclusive) will be administered a single dose of ipatasertib (100 mg).
|
A single oral dose of 100 mg ipatasertib will be administered.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Area Under the Plasma Concentration-Time Curve (AUC) from 0 to Infinity (AUC0-inf) of Ipatasertib
Periodo de tiempo: up to Day 15
|
AUC0-inf is defined as AUC extrapolated from Hour 0 to infinity of ipatasertib in the plasma.
|
up to Day 15
|
Maximum Observed Plasma Concentration (Cmax) of Ipatasertib
Periodo de tiempo: up to Day 15
|
Maximum observed concentration of ipatasertib as determined by measuring drug concentration in blood samples over time.
|
up to Day 15
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Percentage of Participants with Treatment-Emergent Adverse Events (AE)
Periodo de tiempo: up to Day 15
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment.
An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.
Preexisting conditions which worsen during a study are also considered as adverse events.
|
up to Day 15
|
Time to Reach Maximum Observed Concentration (tmax) of Ipatasertib
Periodo de tiempo: up to Day 15
|
Time from dose administration to observed maximum serum concentration for ipatasertib as determined by measuring drug concentration in blood samples over time.
|
up to Day 15
|
AUC from 0 to last measurable concentration (AUC0-t)
Periodo de tiempo: up to Day 15
|
Area under the plasma concentration-time curve from Hour 0 to the last measurable concentration of ipatasertib.
|
up to Day 15
|
Half-life (t1/2) of Ipatasertib
Periodo de tiempo: up to Day 15
|
Half-life of ipatasertib is the time elapsed for the drug concentration to decrease by half as determined by measuring drug concentration in blood samples over time.
|
up to Day 15
|
Apparent Plasma Clearance (CL/F) of Ipatasertib
Periodo de tiempo: Up to Day 15
|
Apparent clearance (CL/F) of ipatasertib, where CL is clearance and F is bioavailability (relative amount of extravascularly-administered drug that reaches systemic circulation unchanged).
Determined by measuring drug concentration in blood samples over time.
|
Up to Day 15
|
Apparent Volume of Distribution (V/F) of Ipatasertib
Periodo de tiempo: up to Day 15
|
Apparent volume of distribution (V/F) during the terminal phase of ipatasertib.
|
up to Day 15
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- GP40200
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Ipatasertib
-
Genentech, Inc.TerminadoVoluntario SaludableEstados Unidos
-
Genentech, Inc.Terminado
-
Hoffmann-La RocheTerminado
-
Genentech, Inc.Terminado
-
Institute of Cancer Research, United KingdomHoffmann-La RocheReclutamientoTumor solido | Glioblastoma multiforme | Cáncer de próstata metastásicoReino Unido
-
SOLTI Breast Cancer Research GroupRoche Pharma AGReclutamientoCáncer de mama metastásicoEspaña
-
Jun Zhang, MD, PhDUniversity of Iowa; University of KentuckyReclutamientoNSCLC Etapa IV | CPNM en estadio IIIBEstados Unidos
-
Hoffmann-La RocheReclutamientoCáncerCorea, república de, Reino Unido, Japón, Costa Rica, Bélgica, Taiwán, Federación Rusa, México, Polonia, Francia
-
Hoffmann-La RocheTerminadoCáncer de mama triple negativoIsrael, Estados Unidos, Australia, Corea, república de, Bélgica, Argentina, Dinamarca, Finlandia, Italia, Portugal, España, Taiwán, Tailandia, Japón, Reino Unido, Brasil, Canadá, Colombia, México, Francia, Costa Rica, Suiza, Chequia, Pol... y más
-
Genentech, Inc.TerminadoNeoplasias de mamaEstados Unidos, España, Corea, república de, Taiwán, Italia, Singapur, Francia, Bélgica